Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2012

01.10.2012 | Review Article

Clinical trials and future potential of targeted therapy for ovarian cancer

verfasst von: Hiroaki Itamochi, Junzo Kigawa

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer is the leading cause of death in women with gynecological cancer. Most patients are diagnosed at an advanced stage with a poor prognosis. Currently, surgical tumor debulking followed by chemotherapy based on platinum and taxane is the standard treatment for advanced disease. However, these patients remain at great risk for recurrence and developing drug resistance. Therefore, new treatment strategies are needed to improve outcomes for patients with advanced and recurrent ovarian cancer. Several agents targeted at particular molecules have been developed for ovarian cancer and are now entering clinical trials. The functional targets of these agents are aberrations in tumor tissues including angiogenesis, the human epidermal growth factor receptor family, poly(ADP-ribose) polymerase (PARP), mammalian target of rapamycin (mTOR) signaling pathway, and α-folate receptor (α-FR). The anti-angiogenic compound bevacizumab has been reported as the most effective targeted agent. Bevacizumab plus chemotherapy prolonged progression-free survival (PFS) both for advanced and platinum-sensitive recurrent ovarian cancer, but did not increase overall survival. A PARP inhibitor, olaparib, applied as maintenance treatment also improved PFS in platinum-sensitive relapsed ovarian cancer. Furthermore, mTOR inhibitors and a monoclonal antibody to α-FR, farletuzumab, are attractive treatment strategies either alone or combined with chemotherapy. Understanding the tumor molecular biology and identifying predictive biomarkers are essential steps in selecting the best treatment strategies. This article reviews available clinical data on the most promising targeted agents for ovarian cancer.
Literatur
1.
Zurück zum Zitat Heintz AP, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S192 Heintz AP, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S192
2.
Zurück zum Zitat Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259PubMedCrossRef Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259PubMedCrossRef
3.
Zurück zum Zitat Markman M, Markman J, Webster K et al (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120–3125PubMedCrossRef Markman M, Markman J, Webster K et al (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120–3125PubMedCrossRef
4.
Zurück zum Zitat Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3:502–516PubMedCrossRef Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3:502–516PubMedCrossRef
5.
Zurück zum Zitat Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59:111–137PubMedCrossRef Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59:111–137PubMedCrossRef
6.
Zurück zum Zitat Itamochi H (2010) Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem 1:209–220PubMedCrossRef Itamochi H (2010) Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem 1:209–220PubMedCrossRef
7.
8.
Zurück zum Zitat Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364PubMedCrossRef Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364PubMedCrossRef
9.
Zurück zum Zitat Brown MR, Blanchette JO, Kohn EC (2000) Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 14:901–918PubMedCrossRef Brown MR, Blanchette JO, Kohn EC (2000) Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 14:901–918PubMedCrossRef
10.
Zurück zum Zitat Shimogai R, Kigawa J, Itamochi H et al (2008) Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. Int J Gynecol Cancer 18:499–505PubMedCrossRef Shimogai R, Kigawa J, Itamochi H et al (2008) Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. Int J Gynecol Cancer 18:499–505PubMedCrossRef
11.
Zurück zum Zitat Klasa-Mazurkiewicz D, Jarzab M, Milczek T et al (2011) Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol 62:31–40PubMed Klasa-Mazurkiewicz D, Jarzab M, Milczek T et al (2011) Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol 62:31–40PubMed
12.
Zurück zum Zitat Siddiqui GK, Maclean AB, Elmasry K et al (2011) Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis 14:155–161PubMedCrossRef Siddiqui GK, Maclean AB, Elmasry K et al (2011) Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis 14:155–161PubMedCrossRef
13.
Zurück zum Zitat Burger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:5165–5171PubMedCrossRef Burger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:5165–5171PubMedCrossRef
14.
Zurück zum Zitat Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186PubMedCrossRef Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186PubMedCrossRef
15.
Zurück zum Zitat Matulonis UA, Berlin S, Ivy P et al (2009) Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27:5601–5606PubMedCrossRef Matulonis UA, Berlin S, Ivy P et al (2009) Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27:5601–5606PubMedCrossRef
16.
Zurück zum Zitat Biagi JJ, Oza AM, Chalchal HI et al (2011) A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 22:335–340PubMedCrossRef Biagi JJ, Oza AM, Chalchal HI et al (2011) A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 22:335–340PubMedCrossRef
17.
Zurück zum Zitat Baumann KH, du Bois A, Meier W et al (2012) A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol. doi:10.1093/annonc/mds003 Baumann KH, du Bois A, Meier W et al (2012) A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol. doi:10.​1093/​annonc/​mds003
18.
Zurück zum Zitat Matei D, Sill MW, Lankes HA et al (2011) Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 29:69–75PubMedCrossRef Matei D, Sill MW, Lankes HA et al (2011) Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 29:69–75PubMedCrossRef
19.
Zurück zum Zitat Bodnar L, Gornas M, Szczylik C (2011) Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol 123:33–36PubMedCrossRef Bodnar L, Gornas M, Szczylik C (2011) Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol 123:33–36PubMedCrossRef
20.
Zurück zum Zitat Annunziata CM, Walker AJ, Minasian L et al (2010) Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 16:664–672PubMedCrossRef Annunziata CM, Walker AJ, Minasian L et al (2010) Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 16:664–672PubMedCrossRef
21.
Zurück zum Zitat Friedlander M, Hancock KC, Rischin D et al (2010) A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119:32–37PubMedCrossRef Friedlander M, Hancock KC, Rischin D et al (2010) A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119:32–37PubMedCrossRef
22.
Zurück zum Zitat Coleman RL, Broaddus RR, Bodurka DC et al (2006) Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101:126–131PubMedCrossRef Coleman RL, Broaddus RR, Bodurka DC et al (2006) Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101:126–131PubMedCrossRef
23.
Zurück zum Zitat Schilder RJ, Sill MW, Lee RB et al (2008) Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 26:3418–3425PubMedCrossRef Schilder RJ, Sill MW, Lee RB et al (2008) Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 26:3418–3425PubMedCrossRef
24.
Zurück zum Zitat Posadas EM, Kwitkowski V, Kotz HL et al (2007) A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110:309–317PubMedCrossRef Posadas EM, Kwitkowski V, Kotz HL et al (2007) A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110:309–317PubMedCrossRef
25.
Zurück zum Zitat Alberts DS, Liu PY, Wilczynski SP et al (2007) Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 17:784–788PubMedCrossRef Alberts DS, Liu PY, Wilczynski SP et al (2007) Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 17:784–788PubMedCrossRef
26.
Zurück zum Zitat Noguera IR, Sun CC, Broaddus RR et al (2012) Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol 125:640–645PubMedCrossRef Noguera IR, Sun CC, Broaddus RR et al (2012) Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol 125:640–645PubMedCrossRef
27.
Zurück zum Zitat Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591PubMedCrossRef Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591PubMedCrossRef
28.
Zurück zum Zitat Kim KJ, Li B, Houck K et al (1992) The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53–64PubMedCrossRef Kim KJ, Li B, Houck K et al (1992) The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53–64PubMedCrossRef
29.
Zurück zum Zitat Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844PubMedCrossRef Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844PubMedCrossRef
30.
Zurück zum Zitat Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRef Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRef
31.
Zurück zum Zitat Micha JP, Goldstein BH, Rettenmaier MA et al (2007) A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17:771–776PubMedCrossRef Micha JP, Goldstein BH, Rettenmaier MA et al (2007) A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17:771–776PubMedCrossRef
32.
Zurück zum Zitat Penson RT, Dizon DS, Cannistra SA et al (2010) Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 28:154–159PubMedCrossRef Penson RT, Dizon DS, Cannistra SA et al (2010) Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 28:154–159PubMedCrossRef
33.
Zurück zum Zitat Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483PubMedCrossRef Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483PubMedCrossRef
34.
Zurück zum Zitat Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496PubMedCrossRef Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496PubMedCrossRef
35.
Zurück zum Zitat Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase iii trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045 Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase iii trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045
36.
Zurück zum Zitat Pujade-Lauraine E, Hilpert F, Weber B et al (2012) AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30:LBA5002 Pujade-Lauraine E, Hilpert F, Weber B et al (2012) AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30:LBA5002
37.
Zurück zum Zitat Heckman CA, Holopainen T, Wirzenius M et al (2008) The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 68:4754–4762PubMedCrossRef Heckman CA, Holopainen T, Wirzenius M et al (2008) The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 68:4754–4762PubMedCrossRef
38.
Zurück zum Zitat Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389–4400PubMedCrossRef Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389–4400PubMedCrossRef
39.
Zurück zum Zitat Sonpavde G, Hutson TE (2007) Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9:115–119PubMedCrossRef Sonpavde G, Hutson TE (2007) Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9:115–119PubMedCrossRef
40.
Zurück zum Zitat Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174PubMedCrossRef Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174PubMedCrossRef
41.
Zurück zum Zitat Lafky JM, Wilken JA, Baron AT et al (2008) Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785:232–265PubMed Lafky JM, Wilken JA, Baron AT et al (2008) Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785:232–265PubMed
42.
Zurück zum Zitat Moyer JD, Barbacci EG, Iwata KK et al (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838–4848PubMed Moyer JD, Barbacci EG, Iwata KK et al (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838–4848PubMed
43.
Zurück zum Zitat Gordon AN, Finkler N, Edwards RP et al (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15:785–792PubMedCrossRef Gordon AN, Finkler N, Edwards RP et al (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15:785–792PubMedCrossRef
44.
Zurück zum Zitat Vergote IB, Joly F, Katsaros D et al (2012) Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a GCIG and EORTC-GCG study. J Clin Oncol 30:LBA5000 Vergote IB, Joly F, Katsaros D et al (2012) Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a GCIG and EORTC-GCG study. J Clin Oncol 30:LBA5000
45.
Zurück zum Zitat Franklin MC, Carey KD, Vajdos FF et al (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317–328PubMedCrossRef Franklin MC, Carey KD, Vajdos FF et al (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317–328PubMedCrossRef
46.
Zurück zum Zitat Gordon MS, Matei D, Aghajanian C et al (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324–4332PubMedCrossRef Gordon MS, Matei D, Aghajanian C et al (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324–4332PubMedCrossRef
47.
Zurück zum Zitat Makhija S, Amler LC, Glenn D et al (2010) Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:1215–1223PubMedCrossRef Makhija S, Amler LC, Glenn D et al (2010) Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:1215–1223PubMedCrossRef
48.
Zurück zum Zitat Bookman MA, Darcy KM, Clarke-Pearson D et al (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283–290PubMedCrossRef Bookman MA, Darcy KM, Clarke-Pearson D et al (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283–290PubMedCrossRef
49.
Zurück zum Zitat Campos S, Hamid O, Seiden MV et al (2005) Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 23:5597–5604PubMedCrossRef Campos S, Hamid O, Seiden MV et al (2005) Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 23:5597–5604PubMedCrossRef
50.
Zurück zum Zitat Garcia AA, Sill MW, Lankes HA et al (2012) A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 124:569–574PubMedCrossRef Garcia AA, Sill MW, Lankes HA et al (2012) A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 124:569–574PubMedCrossRef
51.
Zurück zum Zitat Schilder RJ, Sill MW, Chen X et al (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11:5539–5548PubMedCrossRef Schilder RJ, Sill MW, Chen X et al (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11:5539–5548PubMedCrossRef
52.
Zurück zum Zitat Posadas EM, Liel MS, Kwitkowski V et al (2007) A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109:1323–1330PubMedCrossRef Posadas EM, Liel MS, Kwitkowski V et al (2007) A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109:1323–1330PubMedCrossRef
53.
Zurück zum Zitat Schilder RJ, Pathak HB, Lokshin AE et al (2009) Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 113:21–27PubMedCrossRef Schilder RJ, Pathak HB, Lokshin AE et al (2009) Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 113:21–27PubMedCrossRef
54.
Zurück zum Zitat Seiden MV, Burris HA, Matulonis U et al (2007) A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 104:727–731PubMedCrossRef Seiden MV, Burris HA, Matulonis U et al (2007) A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 104:727–731PubMedCrossRef
55.
Zurück zum Zitat Behbakht K, Sill MW, Darcy KM et al (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 123:19–26PubMedCrossRef Behbakht K, Sill MW, Darcy KM et al (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 123:19–26PubMedCrossRef
56.
Zurück zum Zitat Aghajanian C, Blessing JA, Darcy KM et al (2009) A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115:215–220PubMedCrossRef Aghajanian C, Blessing JA, Darcy KM et al (2009) A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115:215–220PubMedCrossRef
57.
Zurück zum Zitat Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–251PubMedCrossRef Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–251PubMedCrossRef
58.
Zurück zum Zitat Gelmon KA, Tischkowitz M, Mackay H et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852–861PubMedCrossRef Gelmon KA, Tischkowitz M, Mackay H et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852–861PubMedCrossRef
59.
Zurück zum Zitat Kaye SB, Lubinski J, Matulonis U et al (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372–379PubMedCrossRef Kaye SB, Lubinski J, Matulonis U et al (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372–379PubMedCrossRef
60.
Zurück zum Zitat Modesitt SC, Sill M, Hoffman JS et al (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109:182–186PubMedCrossRef Modesitt SC, Sill M, Hoffman JS et al (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109:182–186PubMedCrossRef
61.
Zurück zum Zitat Mackay HJ, Hirte H, Colgan T et al (2010) Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 46:1573–1579PubMedCrossRef Mackay HJ, Hirte H, Colgan T et al (2010) Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 46:1573–1579PubMedCrossRef
62.
Zurück zum Zitat Bell-McGuinn KM, Matthews CM, Ho SN et al (2011) A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121:273–279PubMedCrossRef Bell-McGuinn KM, Matthews CM, Ho SN et al (2011) A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121:273–279PubMedCrossRef
63.
Zurück zum Zitat Usha L, Sill MW, Darcy KM et al (2011) A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol 121:455–461PubMedCrossRef Usha L, Sill MW, Darcy KM et al (2011) A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol 121:455–461PubMedCrossRef
64.
Zurück zum Zitat Baumann K, Pfisterer J, Wimberger P et al (2011) Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 123:27–32PubMedCrossRef Baumann K, Pfisterer J, Wimberger P et al (2011) Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 123:27–32PubMedCrossRef
65.
Zurück zum Zitat Gold MA, Brady WE, Lankes HA et al (2012) A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125:635–639PubMedCrossRef Gold MA, Brady WE, Lankes HA et al (2012) A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125:635–639PubMedCrossRef
66.
Zurück zum Zitat Rouleau M, Patel A, Hendzel MJ et al (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293–301PubMedCrossRef Rouleau M, Patel A, Hendzel MJ et al (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293–301PubMedCrossRef
67.
Zurück zum Zitat Press JZ, De Luca A, Boyd N et al (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17PubMedCrossRef Press JZ, De Luca A, Boyd N et al (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17PubMedCrossRef
68.
Zurück zum Zitat The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615CrossRef The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615CrossRef
69.
Zurück zum Zitat Konstantinopoulos PA, Spentzos D, Karlan BY et al (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28:3555–3561PubMedCrossRef Konstantinopoulos PA, Spentzos D, Karlan BY et al (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28:3555–3561PubMedCrossRef
70.
Zurück zum Zitat Weberpals JI, Clark-Knowles KV, Vanderhyden BC (2008) Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 26:3259–3267PubMedCrossRef Weberpals JI, Clark-Knowles KV, Vanderhyden BC (2008) Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 26:3259–3267PubMedCrossRef
71.
Zurück zum Zitat Ledermann J, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382–1392PubMedCrossRef Ledermann J, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382–1392PubMedCrossRef
72.
Zurück zum Zitat Bellacosa A, de Feo D, Godwin AK et al (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280–285PubMedCrossRef Bellacosa A, de Feo D, Godwin AK et al (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280–285PubMedCrossRef
73.
Zurück zum Zitat Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501PubMedCrossRef Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501PubMedCrossRef
74.
Zurück zum Zitat Altomare DA, Wang HQ, Skele KL et al (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23:5853–5857PubMedCrossRef Altomare DA, Wang HQ, Skele KL et al (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23:5853–5857PubMedCrossRef
75.
Zurück zum Zitat Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119:243–250PubMedCrossRef Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119:243–250PubMedCrossRef
76.
Zurück zum Zitat Elnakat H, Ratnam M (2006) Role of folate receptor genes in reproduction and related cancers. Front Biosci 11:506–519PubMedCrossRef Elnakat H, Ratnam M (2006) Role of folate receptor genes in reproduction and related cancers. Front Biosci 11:506–519PubMedCrossRef
77.
Zurück zum Zitat Kalli KR, Oberg AL, Keeney GL et al (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108:619–626PubMedCrossRef Kalli KR, Oberg AL, Keeney GL et al (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108:619–626PubMedCrossRef
78.
Zurück zum Zitat Chen YL, Chang MC, Huang CY et al (2012) Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 6:360–369PubMedCrossRef Chen YL, Chang MC, Huang CY et al (2012) Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 6:360–369PubMedCrossRef
79.
Zurück zum Zitat Toffoli G, Cernigoi C, Russo A et al (1997) Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193–198PubMedCrossRef Toffoli G, Cernigoi C, Russo A et al (1997) Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193–198PubMedCrossRef
80.
Zurück zum Zitat Bottero F, Tomassetti A, Canevari S et al (1993) Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 53:5791–5796PubMed Bottero F, Tomassetti A, Canevari S et al (1993) Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 53:5791–5796PubMed
81.
Zurück zum Zitat Ebel W, Routhier EL, Foley B et al (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7:6PubMed Ebel W, Routhier EL, Foley B et al (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7:6PubMed
82.
Zurück zum Zitat Konner JA, Bell-McGuinn KM, Sabbatini P et al (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16:5288–5295PubMedCrossRef Konner JA, Bell-McGuinn KM, Sabbatini P et al (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16:5288–5295PubMedCrossRef
83.
Zurück zum Zitat Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24:1053–1065PubMedCrossRef Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24:1053–1065PubMedCrossRef
84.
Zurück zum Zitat Schmeler KM, Gershenson DM (2008) Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep 10:519–523PubMedCrossRef Schmeler KM, Gershenson DM (2008) Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep 10:519–523PubMedCrossRef
85.
Zurück zum Zitat Hsu CY, Bristow R, Cha MS et al (2004) Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 10:6432–6436PubMedCrossRef Hsu CY, Bristow R, Cha MS et al (2004) Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 10:6432–6436PubMedCrossRef
86.
Zurück zum Zitat Jones S, Wang TL, Kurman RJ et al (2012) Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226:413–420PubMedCrossRef Jones S, Wang TL, Kurman RJ et al (2012) Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226:413–420PubMedCrossRef
87.
Zurück zum Zitat Romero I, Bast RC Jr (2012) Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153:1593–1602PubMedCrossRef Romero I, Bast RC Jr (2012) Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153:1593–1602PubMedCrossRef
88.
Zurück zum Zitat Farley J, Brady W, Birrer M et al (2012) A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. Annual meeting of AACR CT-05 Farley J, Brady W, Birrer M et al (2012) A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. Annual meeting of AACR CT-05
89.
Zurück zum Zitat Campbell IG, Russell SE, Choong DY et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678–7681PubMedCrossRef Campbell IG, Russell SE, Choong DY et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678–7681PubMedCrossRef
90.
Zurück zum Zitat Willner J, Wurz K, Allison KH et al (2007) Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 38:607–613PubMedCrossRef Willner J, Wurz K, Allison KH et al (2007) Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 38:607–613PubMedCrossRef
91.
Zurück zum Zitat Kuo KT, Mao TL, Jones S et al (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174:1597–1601PubMedCrossRef Kuo KT, Mao TL, Jones S et al (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174:1597–1601PubMedCrossRef
92.
Zurück zum Zitat Obata K, Morland SJ, Watson RH et al (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095–2097PubMed Obata K, Morland SJ, Watson RH et al (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095–2097PubMed
93.
Zurück zum Zitat Gamallo C, Palacios J, Moreno G et al (1999) Beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155:527–536PubMedCrossRef Gamallo C, Palacios J, Moreno G et al (1999) Beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155:527–536PubMedCrossRef
94.
Zurück zum Zitat Ichikawa Y, Nishida M, Suzuki H et al (1994) Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54:33–35PubMed Ichikawa Y, Nishida M, Suzuki H et al (1994) Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54:33–35PubMed
95.
Zurück zum Zitat Gemignani ML, Schlaerth AC, Bogomolniy F et al (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90:378–381PubMedCrossRef Gemignani ML, Schlaerth AC, Bogomolniy F et al (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90:378–381PubMedCrossRef
Metadaten
Titel
Clinical trials and future potential of targeted therapy for ovarian cancer
verfasst von
Hiroaki Itamochi
Junzo Kigawa
Publikationsdatum
01.10.2012
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2012
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0459-8

Weitere Artikel der Ausgabe 5/2012

International Journal of Clinical Oncology 5/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.